Clinical Trials for Other Solid Tumor

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates the use of autologous tumor-infiltrating lymphocytes (TIL) therapy, either alone or in combination with checkpoint inhibitors, for patients with unresectable or metastatic melanoma, advanced/metastatic squamous cell carcinoma of the head and neck, and non-small cell lung cancer, who have experienced disease progression after prior therapies. The trial involves TIL preparations LN-144 (Lifileucel), LN-145, and LN-145-S1, and aims to enhance antitumor immune responses through adoptive cell transfer, with optional checkpoint inhibitors like pembrolizumab, ipilimumab, or nivolumab to boost the immune system.

ClinicalTrials.gov ID: NCT03645928

A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates the efficacy of combining tiragolumab, a TIGIT-targeting monoclonal antibody, with atezolizumab and bevacizumab in patients with advanced non-squamous NSCLC who are either PD-L1 positive and wild-type for EGFR, ALK, and ROS1, or have an activating EGFR mutation after progression on prior therapies.

ClinicalTrials.gov ID: NCT04958811

Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) Alone and in Combination with Pembrolizumab in Subjects with Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) and Progressed After Antibody-drug Conjugates And/or Chemotherapy (TRACY-1)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the use of 225Ac-DOTATATE (RYZ101), an alpha-emitting radiopharmaceutical targeting somatostatin receptor 2, alone or with pembrolizumab, a PD-1 inhibitor, in patients with locally advanced, unresectable, or metastatic ER+, HER2-negative breast cancer that expresses somatostatin receptors and has progressed after previous treatments.

ClinicalTrials.gov ID: NCT06590857

Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination With Intravenous Trastuzumab Deruxtecan (T-DXd) or in Combination With Intravenous Trastuzumab Emtansine (T-DM1) for Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC) and Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the combination of oral zongertinib, a selective HER2 inhibitor, with intravenous trastuzumab deruxtecan (T-DXd) or trastuzumab emtansine (T-DM1) in adult patients with HER2+ metastatic breast cancer or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, who have progressive disease and have experienced unsuccessful prior treatments.

ClinicalTrials.gov ID: NCT06324357

A Phase 2a Study With Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: The trial is targeting adults with advanced urothelial carcinoma and non-small cell lung cancer who have progressed after PD-1/PD-L1 therapy, evaluating a liposomal gemcitabine formulation (FF-10832) for enhanced drug delivery and tumor targeting, either alone or combined with pembrolizumab, an immune checkpoint inhibitor.

ClinicalTrials.gov ID: NCT05318573

A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial targets adults with metastatic solid tumors harboring KRAS G12D or G12V mutations who are refractory to standard treatments, testing the combination of KRAS TCR-transduced peripheral blood lymphocytes (PBL) and high-dose aldesleukin, alongside a novel neoantigen vaccine (GRT-C903 and GRT-R904) using an adenoviral vector and self-amplifying mRNA to induce KRAS-specific immune responses.

ClinicalTrials.gov ID: NCT06253520

A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls patients with advanced or metastatic solid tumors, including those with BRAF V600 mutations or Class II/III BRAF alterations, to evaluate PF-07799544, an investigational MEK inhibitor that penetrates the blood-brain barrier, both as monotherapy and in combination with PF-07799933, a selective pan-mutant BRAF inhibitor.

ClinicalTrials.gov ID: NCT05538130

An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination with Pembrolizumab in Participants with Advanced And/or Refractory Solid Tumor Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with advanced or refractory solid tumors treated with GV20-0251, a monoclonal antibody targeting IGSF8, as monotherapy or in combination with the PD-1 inhibitor pembrolizumab, aimed at enhancing immune responses and assessing synergistic effects.

ClinicalTrials.gov ID: NCT05669430

A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530, an Autologous Logic-gated Tmod™ Chimeric Antigen Receptor T Cell (CAR T), in Heterozygous HLA-A*02 Adult Subjects with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates A2B530 CAR T-cell therapy in adult patients with recurrent unresectable, locally advanced, or metastatic solid tumors expressing carcinoembryonic antigen (CEA) and loss of HLA-A*02 expression, including colorectal, pancreatic, and non-small cell lung cancers. A2B530 uses a novel Tmod platform with dual receptor targeting to selectively destroy tumor cells while sparing healthy cells.

ClinicalTrials.gov ID: NCT05736731

A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial aims to assess the safety and activity of divarasib, a selective KRAS G12C inhibitor, in combination with pembrolizumab and chemotherapy in patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, excluding those with squamous cell histology or other targetable oncogenic drivers.

ClinicalTrials.gov ID: NCT05789082